Podcast: Multidisciplinary Task Force: Diagnosis and Management of Dedifferentiated Liposarcoma

STATEMENT OF NEED

Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, pathologists, nurse practitioners, physician assistants/associates and other healthcare professionals involved in the treatment of patients with soft tissue sarcoma.